A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals
Clinical trial NCT05208125 · COMPLETED
Trial details
- NCT number
- NCT05208125
- Sponsor
- IrsiCaixa
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-30
- Primary completion
- 2022-03-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.